Security Snapshot

X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR) Institutional Ownership

CUSIP: 98420X103

13F Institutional Holders and Ownership History from Q1 2019 to Q2 2026

13F reference period

Q2 2026

Institutions Reporting

1

Shares (Excl. Options)

3.23MFull value: 3,233,743 · shares · 30 Jun 2026

Price

$4.67

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, par value $0.001 per share
Symbol
XFOR on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
3,233,743
Latest holder snapshot 4 signals
Total 13F value
$15,101,580
Share change
-234,039
Value change
-$966,583
Number of holders
1
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
94,372,096
SEC-reported price per share
$4.67
Insider filing price
$4.67
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 98420X103.
  • 1 institution reported positions in Q2 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 2 to 1 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $14.32MFull value: $14,321,942 · USD · 31 Mar 2026
    to
    $15.1MFull value: $15,101,580 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 1 institution filings for Q2 2026.

Open SEC evidence

Security key

98420X103

13F reference period

Q2 2026

13F holders

1

13D/G owners

3

CIK / CUSIP context first

Open Q2 2026 holders XFOR full holder history X4 Pharmaceuticals, Inc SEC filings X4 Pharmaceuticals, Inc company facts X4 Pharmaceuticals, Inc insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
XFOR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 4.8% $1,558,172 8,200,903 The Vanguard Group 31 Dec 2024
PERCEPTIVE ADVISORS LLC 7.3% $1,308,941 6,889,163 Perceptive Advisors LLC 31 Mar 2026
ORBIMED ADVISORS LLC 1.7% $25,640 134,947 ORBIMED ADVISORS LLC 30 Jun 2025
As of 30 Jun 2026, 1 institutional investors reported holding
3.23MFull value: 3,233,743 · shares · 30 Jun 2026
shares of X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR). This represents 3.4% of the company’s total
94.37MFull value: 94,372,096 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
30
Headline period
Q2 2026
Rows shown
1-25 of 30
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 3,233,743 $15,101,580 -$966,583 $4.67 1
2026 Q1 3,467,782 $14,321,942 -$162,415 $4.13 2
2025 Q4 3,507,120 $14,028,434 +$4,000,064 $4.00 3
2025 Q3 2,507,092 $8,574,256 +$6,340,007 $3.42 2
2025 Q2 653,289 $1,241,249 -$59,123,616 $1.90 2
2025 Q1 98,484,813 $23,301,713 -$1,452,474 $0.24 91
2024 Q4 99,822,228 $73,237,480 -$4,976,749 $0.73 89
2024 Q3 100,589,647 $67,319,848 -$551,327 $0.67 98
2024 Q2 101,516,641 $58,880,322 -$4,474,635 $0.58 97
2024 Q1 102,998,180 $143,153,751 +$10,326,109 $1.39 96
2023 Q4 96,800,089 $81,168,367 -$18,734,277 $0.84 92
2023 Q3 112,423,967 $122,551,525 -$3,809,593 $1.09 91
2023 Q2 112,930,152 $219,074,939 +$103,525,068 $1.94 96
2023 Q1 60,979,055 $53,052,409 +$698,212 $0.87 56
2022 Q4 60,622,175 $60,205,215 +$20,545,513 $0.99 52
2022 Q3 39,133,898 $66,911,740 +$39,611,313 $1.71 54
2022 Q2 16,046,519 $15,520,101 -$680,561 $0.96 44
2022 Q1 16,343,188 $28,602,538 -$2,230,268 $1.75 52
2021 Q4 17,568,471 $40,229,950 -$2,286,455 $2.29 49
2021 Q3 16,206,198 $85,726,624 -$2,862,733 $5.29 48
2021 Q2 16,587,201 $107,773,003 +$971,565 $6.50 58
2021 Q1 16,126,888 $138,720,293 +$48,924,159 $8.61 59
2020 Q4 10,477,783 $67,370,946 +$1,560,507 $6.43 53
2020 Q3 10,231,522 $69,268,392 -$5,283,243 $6.77 50
2020 Q2 10,703,549 $99,748,639 -$2,349,709 $9.32 54
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .